Phase II/III Double-blind, Randomized Clinical Trial With Active Vaccine Control to Evaluate the Safety, Immunogenicity, and Consistency of the Lots of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine in Adults in Brazil
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 4,400
- 试验地点
- 6
- 主要终点
- Severe adverse events
研究概览
简要总结
NDV-HXP-S is an inactivated COVID-19 vectored-vaccine virus using the Newcastle Disease Virus as basis and expressing Spike (S) protein from SARS-CoV-2 stabilized in pre-fusion form with Hexapro technology.
This vaccine was successfully tested in non-clinical and clinical studies with a good safety profile and eliciting neutralizing antibodies against SARS-CoV-2. Clinical testing is conducted by an international consortium including three different manufacturers. Butantan, in Brazil, is one of them.
详细描述
The present protocol of Phase II/III studies.The Phase II study consists in a randomized (1:1) controlled double-blinded trial that aims to evaluate the safety and immunogenicity of NDV-HXP-S 10μg as a dose of booster in comparison to the vaccine against COVID-19 BNT162b2 30μg in a population of 400 adult subjects (50% with age ≥ 60 years), regardless of past of infection by COVID-19, with proof of two or more doses of COVID-19, of which the last dose administered at least 120 days ago.
The Phase III study consists in a randomized (3:1) controlled double-blinded trial that aims to evaluate the safety, immunogenicity and consistency of three consecutive batches of NDV-HXP-S 10μg as a dose of booster in comparison to the vaccine against COVID-19 BNT162b2 30μg in a population of 4000 adult subjects (20% with age ≥ 60 years), with similar characteristics as the population of Phase II.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
An electronic central randomization system will be used to designate the investigational product (IP) that each participant must receive. A team study non-blind, qualified member (nurse/pharmacist) will obtain the corresponding randomization, will separate the respective IP, will blind the product and deliver it to blind staff. The product will be in a syringe that is in a blister labeled with the sponsor's name, IP code, administration route, IP dose and expiration date. The study non-blind staff will not have contact with the participants, will not have access to identification data or any other involvement with the study, besides randomizing the participant, separating the syringe containing active control or vaccine, checking if the information on the blister label corresponds the information on the cartridge label and the syringe is labeled with the clinical trial code, ID, corresponding visit and investigator's name.
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age ≥ 18 years, of which 50% and 20% were aged ≥60 years in Phase II and Phase III studies, respectively, regardless of previous SARS-CoV-2 infection status, with proof of four doses of any monovalent vaccine against COVID-19, of which the last dose administered at least 120 days to 540 days ago.
- •If pre-existing medical conditions: be in a stable condition that does not require hospitalization or significant changes in therapy during the three months prior to enrollment.
- •Agree to regular contact by phone, electronic means, and/or home visits.
- •Intention to participate in the study, documented by the Informed Consent Form.
排除标准
- •Administration of a vaccine of active or inactivated virus not provided for in the study regimen up to 30 days before the dose of the study vaccine.
- •Use of other COVID-19 vaccination regimen other than the one contemplated in item a. of the inclusion criteria.
- •Angioedema or anaphylactic reaction to previous immunizations.
- •Allergy to egg or chicken.
- •Severe allergic reaction or anaphylaxis to the vaccine or components of the study vaccine.
- •Suspected or confirmed fever within 24 hours prior to vaccination or an axillary temperature greater than 37.8°C* on the day of vaccination (inclusion may be delayed until the subject is fever-free for 24 hours), as well as confirmation of SARS-CoV-2 infection (enrollment should be deferred until the participant has completed 24 hours without fever or until the participant resolves the SARS-CoV-2 infection documented by two negative RT-PCR tests).
- •Evidence of uncontrolled active neurological, cardiac, pulmonary, liver or kidney disease. Significant treatment changes or hospitalizations for worsening the condition in the last three months are indicators of uncontrolled disease.
- •Bleeding disorders (e.g., clotting factor deficiency, coagulopathy, platelet dysfunction), or previous history of significant bleeding or bruising after intramuscular injection or venipuncture.
- •Neoplastic diseases (except basal cell carcinoma and cervical carcinoma in situ) diagnosed or under investigation.
- •Suspected or confirmed immune compromising diseases including congenital or acquired immunodeficiencies and autoimmune diseases not under control according to the medical history or physical examination, including asplenia. Significant treatment changes or hospitalizations for worsening the condition in the last three months are indicators of uncontrolled disease.
- •Use of immunosuppressive therapies six months prior to study inclusion or scheduled to be of service within two years of inclusion. The dose of corticosteroid considered immunosuppressive is the equivalent of prednisone at a dose of 20 mg/day for adults for more than 14 days. Continued use of topical or nasal corticosteroids and other topical immunomodulators or immunosuppressants will not be considered immunosuppressive. The following are considered immunosuppressive therapies: antineoplastic chemotherapy, radiotherapy, immunosuppressants to induce transplant tolerance, immunosuppressive and immunobiological treatments in patients with autoimmune rheumatic diseases, among others.
- •Use of blood products (transfusions or immunoglobulins) within the last three months prior to study inclusion or scheduled blood product or immunoglobulin administration within six months of study inclusion.
- •Alcohol or drug abuse in the past 12 months prior to the subject's inclusion.
- •Behavioral, cognitive, or psychiatric illness that affects the subject's ability to understand and cooperate with the study protocol requirements.
- •Being team member conducting the study or having a dependent relationship with one of the study team members.
- •Any other condition that may jeopardize the safety or rights of a potential participant or prevent him/her from complying with this protocol.
- •Abnormalities in screening laboratory tests are considered to be excludable in the opinion of the principal investigator or his/her medical representative. If any changes in the tests are considered temporary, the tests may be repeated up to three times during the screening period (Phase II only)
- •Positive serology tests for human immunodeficiency virus (anti-HIV1/2 ELISA); Hepatitis B (HbsAg or Anti-HBc) or Hepatitis C (total Anti-HCV ELISA).
- •Any other findings that the investigator expect to would increase the risk of adverse outcomes from study participation.
- •For women of childbearing potential:
- •Pregnancy (confirmed by positive β-hCG test), being a breastfeeding, and/or manifest intention to have sexual practices with reproductive potential without the use of a contraceptive method (abstinence, sterilization, intrauterine or implantable contraceptive device; oral contraceptives; diaphragm or condom in combination with contraceptive gel, cream, or foam) within 30 days before and 28 days after vaccination.
- •Note: * The temperature measured with a temporal scanner skin thermometer is considered equivalent to the axillary temperature.
研究组 & 干预措施
NDV-HXP-S 10μg (Phase II)
In the Phase III, 200 adult subjects will be assigned to receive NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety and immunogenicity.
干预措施: NDV-HXP-S 10μg (Biological)
BNT162b2 30μg (Phase II)
In the Phase III, 200 adult subjects will be assigned to receive vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety and immunogenicity.
干预措施: BNT162b2 30μg (Biological)
NDV-HXP-S 10μg batch 1 (Phase III)
In the Phase III, 1000 adult subjects will be assigned to receive the first consecutive batch of NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity and consistency of batches.
干预措施: NDV-HXP-S 10μg (Biological)
NDV-HXP-S 10μg batch 2 (Phase III)
In the Phase III, 1000 adult subjects will be assigned to receive the second consecutive batch of NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity and consistency of batches.
干预措施: NDV-HXP-S 10μg (Biological)
NDV-HXP-S 10μg batch 3 (Phase III)
In the Phase III, 1000 adult subjects will be assigned to receive the third consecutive batch of NDV-HXP-S 10μg/0.5mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity and consistency of batches.
干预措施: NDV-HXP-S 10μg (Biological)
BNT162b2 30μg (Phase III)
In the Phase III, 1000 adult subjects will be assigned to receive the vaccine against COVID-19 BNT162b2 30μg/0.3mL intramuscular (deltoid), booster, 1 dose. All the population will be evaluated for safety. Of them, 250 will be evaluated for immunogenicity only.
干预措施: BNT162b2 30μg (Biological)
结局指标
主要结局
Severe adverse events
时间窗: Within 28 days after vaccination booster dose
Frequency, intensity and relatedness of severe adverse events.
Seroconversion Neutralization GMT SARS-CoV-2 pseudovirus
时间窗: Up to 28 days after vaccination booster dose
Percentage of subjects with Seroconversion Neutralization GMT SARS-CoV-2 pseudovirus.
Neutralization GMTR SARS-CoV-2 pseudovirus
时间窗: Up to 28 days after vaccination booster dose
Neutralization of Geometric mean titer ratio (GMTR) SARS-CoV-2 pseudovirus.
Solicited and unsolicited adverse reactions
时间窗: Within to 7 days after vaccination booster dose
Frequency and intensity of local and systemic solicited and unsolicited adverse reactions.
Unsolicited adverse reactions
时间窗: Within 28 days after vaccination booster dose
Frequency and intensity of all unsolicited grade ≥2 adverse reactions.
次要结局
- Neutralization GMFR SARS-CoV-2 pseudovirus(Up to 28 days after vaccination booster dose)
- GMTR against SARS-CoV-2 (ELISA)(Up to 28 days after vaccination booster dose)
- Serious adverse events(Up to 12 months after vaccine booster dose)
- GMT SARS-CoV-2 pseudovirus(Up to 28 days after vaccination booster dose)
- Adverse events with medical attention(Up to 12 months after vaccine booster dose)
- Seroconversion anti-SARS-CoV-2 ELISA(Up to 28 days after vaccination booster dose)
- Adverse events of special interest(Up to 12 months after vaccine booster dose)
- GMFR against SARS-CoV-2 (ELISA)(Up to 28 days after vaccination booster dose)
- GMT against SARS-CoV-2 (ELISA)(Up to 3 and 12 months after vaccine booster dose)
- Neutralization GMT against SARS-CoV-2 pseudovirus (variants of concern)(Up to 28 days after vaccination booster dose)
- T cell-mediated response against SARS-CoV-2(Up to 12 months after vaccine booster dose)
- Unsolicited adverse events(Up to12 months after vaccine booster dose)
- Hematologic and biochemical assessments (Phase II)(Up to 7 days after vaccine booster dose)